{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:30:22Z","timestamp":1786113022434,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01583-y","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:55:58Z","timestamp":1785948958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of adult acute lymphoblastic leukemia\u2014a therapeutic revolution in the making"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"1583_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","volume":"406","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Pui CH, Jabbour E. Acute lymphocytic leukaemia. Lancet. 2025;406:950\u201362.","journal-title":"Lancet"},{"key":"1583_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/jamaoncol.2025.0613","volume":"11","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Aldoss I, Jabbour E. Management of Adult Acute Lymphoblastic Leukemia: a Review. JAMA Oncol. 2025;11:771\u20138.","journal-title":"JAMA Oncol"},{"key":"1583_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ajh.27708","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Jabbour E. Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2025;100:1205\u201331.","journal-title":"Am J Hematol"},{"key":"1583_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35872","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Jain N, Litzow MR, Luger SM, Papayannidis C, Ribera JM, et al. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer. 2025;131:e35872.","journal-title":"Cancer"},{"key":"1583_CR5","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2352-3026(23)00064-9","volume":"10","author":"NJ Short","year":"2023","unstructured":"Short NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematology. 2023;10:e382\u2013e8.","journal-title":"Lancet Haematology"},{"key":"1583_CR6","doi-asserted-by":"publisher","unstructured":"Li C, Tong H, Wang H, Ren Y, Qian J, Zhou X, et al. Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2026;16:125. https:\/\/doi.org\/10.1038\/s41408-026-01591-y","DOI":"10.1038\/s41408-026-01591-y"},{"key":"1583_CR7","doi-asserted-by":"crossref","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of adults with philadelphia chromosome\u2013positive acute lymphoblastic leukemia\u2014from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol. 2022;8:1340\u20138.","DOI":"10.1001\/jamaoncol.2022.2398"},{"key":"1583_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.clml.2025.06.019","volume":"25","author":"FG Haddad","year":"2025","unstructured":"Haddad FG, Kantarjian H, Senapati J, Jain N, Short NJ, Jabbour E. SOHO state of the art updates and next questions | Philadelphia chromosome-positive acute lymphoblastic leukemia can be treated with chemotherapy-free regimens without transplant. Clin Lymphoma Myeloma Leuk. 2025;25:711\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1583_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023;98:493\u2013501.","journal-title":"Am J Hematol"},{"key":"1583_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cncr.32558","volume":"126","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, Ribera JM, Kantarjian HM, Dombret H, Ottmann OG, Stein AS, et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 2020;126:304\u201310.","journal-title":"Cancer"},{"key":"1583_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","volume":"146","author":"G Martinelli","year":"2021","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Rambaldi A, et al. Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer. 2021;146:107\u201314.","journal-title":"Eur J Cancer"},{"key":"1583_CR12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","volume":"17","author":"R Assi","year":"2017","unstructured":"Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17:897\u2013901.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1583_CR13","doi-asserted-by":"publisher","unstructured":"Goulart H, Braish J, Short NJ, Jain N, Sasaki K, Kantarjian H, et al. A case report of tyrosine kinaseinhibitor interruption in a patient with multilineage philadelphia-positive acute lymphoblasticleukemia. Acta Haematol. 2026:1\u20136. https:\/\/doi.org\/10.1159\/000551699.","DOI":"10.1159\/000551699"},{"key":"1583_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35773","volume":"131","author":"E Kugler","year":"2025","unstructured":"Kugler E, Kantarjian H, Jabbour E, Khaire N, Short NJ, Kadia TM, et al. Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2025;131:e35773.","journal-title":"Cancer"},{"key":"1583_CR15","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in philadelphia chromosome-positive aLL. J Clin Oncol. 2024;42:4246\u201351.","journal-title":"J Clin Oncol"},{"key":"1583_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1182\/blood-2025-439","volume":"146","author":"S Chiaretti","year":"2025","unstructured":"Chiaretti S, Di Trani M, Skert C, Elia L, Almici G, Della Starza I, et al. First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients. Blood. 2025;146:439.","journal-title":"Blood"},{"key":"1583_CR17","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1200\/JCO.2026.44.16_suppl.6514","volume":"44","author":"LF Nasr","year":"2026","unstructured":"Nasr LF, Goulart H, Short NJ, Jain N, Hachem M, Kadia TM, et al. Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia. J Clin Oncol. 2026;44:6514.","journal-title":"J Clin Oncol"},{"key":"1583_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774\u201382.","journal-title":"Blood"},{"key":"1583_CR19","doi-asserted-by":"publisher","unstructured":"Kantarjian H, Deininger M, Apperley J, Aurthur C, Chuah C, Hochhaus A, et al. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. Leukemia (2026). https:\/\/doi.org\/10.1038\/s41375-026-03009-x","DOI":"10.1038\/s41375-026-03009-x"},{"key":"1583_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35832","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Zhai Y, Oehler VG, Jamy O, Koller PB, Haddad FG, et al. Olverembatinib in chronic myeloid leukemia\u2014Review of historical development, current status, and future research. Cancer. 2025;131:e35832.","journal-title":"Cancer"},{"key":"1583_CR21","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-025-02674-8","volume":"39","author":"X Gong","year":"2025","unstructured":"Gong X, Liu W, Liu Y, Fang Q, Gu R, Liu K, et al. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial. Leukemia. 2025;39:1838\u201347.","journal-title":"Leukemia"},{"key":"1583_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","volume":"11","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, et al. Olverembatinib after failure of tyrosine kinase inhibitors, including Ponatinib or Asciminib: a phase 1b randomized clinical trial. JAMA Oncol. 2025;11:28\u201335.","journal-title":"JAMA Oncol"},{"key":"1583_CR23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1182\/blood-2025-442","volume":"146","author":"R Gu","year":"2025","unstructured":"Gu R, Qiu S, Gong X, Wei S, Zhang G, Gong B, et al. Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: a prospective phase 2 study. Blood. 2025;146:442.","journal-title":"Blood"},{"key":"1583_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","volume":"18","author":"NJ Short","year":"2025","unstructured":"Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, et al. Molecular characterization and predictors of relapse in patients with Ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab. J Hematol Oncol. 2025;18:55.","journal-title":"J Hematol Oncol"},{"key":"1583_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1182\/blood-2025-648","volume":"146","author":"A DiNofia","year":"2025","unstructured":"DiNofia A, Myers R, Li Y, Liu H, Aplenc R, Baniewicz D, et al. CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL. Blood. 2025;146:648.","journal-title":"Blood"},{"key":"1583_CR26","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1182\/blood-2025-3350","volume":"146","author":"H Goulart","year":"2025","unstructured":"Goulart H, Jabbour E, Jain N, Ravandi F, Kadia T, DiNardo C, et al. Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab. Blood. 2025;146:3350.","journal-title":"Blood"},{"key":"1583_CR27","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330.","journal-title":"N Engl J Med"},{"key":"1583_CR28","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667\u201378.","journal-title":"Nat Med"},{"key":"1583_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024;391:320\u201333.","journal-title":"N Engl J Med"},{"key":"1583_CR30","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/JCO.24.00490","volume":"42","author":"P Chevallier","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, et al. Inotuzumab Ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2024;42:4327\u201341.","journal-title":"J Clin Oncol"},{"key":"1583_CR31","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","volume":"129","author":"MB Geyer","year":"2017","unstructured":"Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017;129:1878\u201381.","journal-title":"Blood"},{"key":"1583_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","volume":"115","author":"AV Moorman","year":"2010","unstructured":"Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115:206\u201314.","journal-title":"Blood"},{"key":"1583_CR33","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1200\/JCO-25-00307","volume":"43","author":"MJ Wieduwilt","year":"2025","unstructured":"Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, et al. Inotuzumab Ozogamicin then blinatumomab for older adults with newly diagnosed B-cell ALL: alliance study A041703 Cohort 1 results. J Clin Oncol. 2025;43:3526\u201335.","journal-title":"J Clin Oncol"},{"key":"1583_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2025-443","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Wang X, Zhang J, Guan M, Espinosa R, Clark M, et al. CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission. Blood. 2025;146:443.","journal-title":"Blood"},{"key":"1583_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajh.27576","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, et al. Hyper-CVAD and Sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Am J Hematol. 2025;100:402\u20137.","journal-title":"Am J Hematol"},{"key":"1583_CR36","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1182\/blood-2025-1567","volume":"146","author":"H Goulart","year":"2025","unstructured":"Goulart H, Kantarjian H, Jain N, Khouri R, Kadia T, DiNardo C, et al. The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: four-year follow-up of a phase 2 study. Blood. 2025;146:1567.","journal-title":"Blood"},{"key":"1583_CR37","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10:e433\u20134.","journal-title":"Lancet Haematol"},{"key":"1583_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N, W\u00e4sch R, Kondakci M, Scholl S, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol. 2024;42:273\u201382.","journal-title":"J Clin Oncol"},{"key":"1583_CR39","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2023-180472","volume":"142","author":"N Goekbuget","year":"2023","unstructured":"Goekbuget N, Schwartz S, Faul C, Topp MS, Subklewe M, Renzelmann A, et al. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial. Blood. 2023;142:964.","journal-title":"Blood"},{"key":"1583_CR40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood-2023-174973","volume":"142","author":"S Chiaretti","year":"2023","unstructured":"Chiaretti S, Della Starza I, Santoro A, Spinelli O, Elia L, De Propris MS, et al. sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph- B-lineage acute lymphoblastic leukemia. final results of the phase II Gimema LAL2317 Trial. Blood. 2023;142:826.","journal-title":"Blood"},{"key":"1583_CR41","doi-asserted-by":"publisher","unstructured":"Boissel N, Huguet F, Leguay T, Hunault M, Kim R, Hicheri Y, et al. Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014\/B-QUEST study. Blood. 2026;148:289\u201399. https:\/\/doi.org\/10.1182\/blood.2026033309.","DOI":"10.1182\/blood.2026033309"},{"key":"1583_CR42","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1200\/JCO.2026.44.16_suppl.6516","volume":"44","author":"M Hachem","year":"2026","unstructured":"Hachem M, Goulart H, Jain N, Nasr LF, Ravandi-Kashani F, Kadia TM, et al. The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia. J Clin Oncol. 2026;44:6516.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01583-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01583-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01583-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:55:59Z","timestamp":1785948959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01583-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01583-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Honoraria\/Advisory Board\/Consulting: AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline,Takeda Research Grants: AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Novartis.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"131"}}